Healthcare Industry News: computer-aided detection
News Release - April 26, 2006
HealthTrust Purchasing Group Awards Mammography CAD Contract to iCAD, Inc. for SecondLook(R) Computer Aided Detection SystemsHealthTrust Members Now Have Access to Savings on Early Breast Cancer Detection
NASHUA, N.H., April 26 (HSMN NewsFeed) -- iCADŽ, Inc. (Nasdaq: ICAD ), provider of Computer Aided Detection (CAD) solutions with industry leading detection in subtle forms of breast cancer, and HealthTrust Purchasing Group (HealthTrust), today announced an agreement that gives HealthTrust members access to SecondLook Computer Aided Detection systems for use with mammography.
An increasing number of radiologists use computer-aided detection as a "second pair of eyes" when reading a mammogram. iCAD has the potential to detect findings that might otherwise be overlooked during the review process, thus increasing cancer detection. iCAD technology is especially effective in identifying difficult to see calcifications. Clinical trials demonstrated that use of the SecondLook CAD systems could detect up to 68% of actionable missed breast cancers an average of 15 months earlier than screening mammography alone.
About HealthTrust Purchasing Group
HealthTrust Purchasing Group (HealthTrust), headquartered in Brentwood, Tennessee, is a group purchasing organization that supports not-for-profit and for-profit acute care hospitals, ambulatory surgery centers, alternate care sites, and physician practices. HealthTrust is committed to obtaining the best price for clinically-recommended products, ensuring their timely delivery and continuously evaluating and improving our services to the patients, physicians and clinicians they serve. For more information, please visit http://www.healthtrustpg.com.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of computer-aided detection (CAD) solutions that enable healthcare professionals to identify cancer and other life-threatening conditions earlier by making medical services more effective, more accessible and more affordable for patients worldwide. Recipient of Frost & Sullivan's Growth Strategy Leadership award, iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. As the most frequently selected CAD solution for film-based and digital breast screening, iCAD is entrusted with the task of early cancer detection by over eleven hundred women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
iCAD and SecondLook are registered trademarks of iCAD, Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.